This sixth podcast program, Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities, features an interview with Professor McInnes. He discusses the current state of knowledge in rheumatoid arthritis and directions for discov

Episode 5: Progress and Prognosis: Evaluating Patients' Responses to Biologic Therapy

Feb 6th, 2009 16m 18s

This fifth podcast titled Progress and Prognosis: Evaluating Patients’ Responses to Biologic Therapy features a telephone interview with Professor Schett. He discusses differences among the anti-TNF agents in the treatment of rheumatoi

Episode 4: Individualizing Treatment in Rheumatoid Arthritis: The Crucial Impact of Patient Heterogeneity

Dec 5th, 2008 14m 21s

Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgrou

Episode 3: Anti-TNF Treatment: Focus on early Rheumatoid Arthritis. Featuring an interview with Professor Paul Emery

Oct 3rd, 2008 14m 21s

Contemporary research shows that the early diagnosis and treatment of RA can offer patients the possibility of achieving remission. The goal for any patient with early RA should be to achieve remission. If a patient does not already

Episode 2: Establishing the Evidence: Clinical Trials with TNF Inhibitors

Aug 27th, 2008 14m 53s

Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only cli

Episode 1: TNF-Alpha: Concept to Proof of Concept

May 30th, 2008 14m 53s

Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini

Rate